Navigation Links
Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy

SAN FRANCISCO, Nov. 8, 2011 /PRNewswire/ -- OrbusNeich today announced that three-year clinical outcomes data from the use of the Genous Stent in a large, real-world patient population demonstrate the device's long-term safety and efficacy. These results were published in the October issue of the Journal of Interventional Cardiology.

At three-year clinical follow-up, the study's primary endpoint, a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR), in an unselected patient population was 18.3%. Between one and three years, TLR had increased by only 3.6%, and no cases of late and very late definite stent thrombosis (ST) were observed.

"This is the first report of three-year clinical outcomes for the Genous Stent, and it is important to recognize that only a small number of studies have ever reported on three-year outcomes following percutaneous coronary intervention with stent placement in an all-comer population," said Margo Klomp, M.D., of the Academic Medical Center, Amsterdam, and lead author of the publication. "The target lesion failure rate of 18.3% in this case is on the lower end of the spectrum versus reported DES outcomes. In addition, late and very late ST was absent in our Genous Stent treated cohort, whereas other registries have reported occurrence of late and very late ST in DES treated patients."

The single-center study included 405 unselected patients with mostly complex lesions with an estimated high risk of restenosis. Specifically, 47% of the patients had multivessel disease, and, of the lesions treated, 75% were type B2/C lesions, 20% were chronic total occlusion (CTO) lesions, and 24% were bifurcated lesions. The average stent length was 24.6 +/- 11.7 mm. Patients were treated with clopidogrel for one month, and 16 patients received clopidogrel for less than one month. The duration of aspirin administration was indefinite.

"For patients treated with Genous, our typical prescription of dual antiplatelet therapy (DAPT) is 30 days," said Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam. "In this large, unselected patient population, there was also a segment of patients who were contraindicated to long-term DAPT and thus received less than 30 days of DAPT. For this reason, it was particularly striking there were only two cases of early stent thrombosis and that no thrombosis was observed after one month through the three year follow up, attesting to the excellent safety profile of Genous in a real world setting."

Please visit the following link to hear Prof. de Winter discuss these data:

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel:

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
9. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
10. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... it will be sharing additional findings from the multicenter ... Therapeutics (TCT) meeting in San Francisco ... Device , announced that it will be sharing additional ... community at the Trans-Catheter Therapeutics (TCT) meeting in ...
(Date:10/13/2015)... , Oct. 13, 2015  The spine division of ... in musculoskeletal healthcare, will showcase its portfolio of innovative ... Society (NASS) annual meeting, October 14-17, 2015, in ... host two clinical events: "Supplemental MIS Fixation ... Wednesday, October 14 12:30 – 1 p.m. --> ...
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Sir Grout of Greater Boston donated an expansive, seven room ... McDonald House Charities® (RMHC®). This donation was made in an effort to give back ... its inception. , “We believe strongly in the Ronald McDonald House Charities, and they ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):